Funder: Eli Lilly and Company
Due Dates: February 15, 2026: Full application deadline — Efficacy of Lebrikizumab in fibrosing skin conditions | February 15, 2026: Full application deadline — Lebrikizumab impact on post-inflammatory dyspigmentation in atopic dermatitis | June 15, 2026: Full application deadline — Real-world effectiveness of mirikizumab in IBD/epidemiology in overweight/obese (Canada)
Funding Amounts: Financial support and/or study drug provided; award amount and duration vary by project and RFP scope.
Summary: Supports investigator-initiated clinical research in Lilly-prioritized therapeutic areas through a competitive RFP process.
Key Information: Grantee is responsible for study design, conduct, and regulatory sponsorship.